Seeking Alpha
 

St. Jude Medical, Inc. (STJ)

- NYSE
  • Jul. 18, 2012, 8:00 AM
    St. Jude Medical (STJ): Q2 EPS of $0.86 misses by $0.01. Revenue of $1.41B (-2.5% Y/Y). (PR)
    | Comment!
  • Jul. 18, 2012, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV, ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB
    | Comment!
  • Jul. 17, 2012, 5:30 PM
    Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV,ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB
    | Comment!
  • Jul. 16, 2012, 9:27 AM
    St. Jude Medical (STJ) says that the erosion of leads for its recalled Riata defibrillator occurred from the inside out most often in cables with larger diameters, the initial findings of a study show. St. Jude faces a class action lawsuit over the leads.
    | Comment!
  • Jun. 28, 2012, 11:32 AM
    The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%.
    | 1 Comment
  • Jun. 25, 2012, 2:34 PM
    Goldman says that St. Jude's (STJ +0.2%) finding that its Durata lead failure was due to external abrasion means initial fears were unfounded and that the performance of the device will support further utilization and not lead to a major negative safety event. The firm continues to rate the shares a Buy. Additionally, Canaccord also reiterates a Buy, recommending investors add to positions.
    | Comment!
  • Jun. 25, 2012, 11:41 AM
    St. Jude (STJ +0.2%) bucks a weak tape after saying late Friday it's identified a single Durata defibrillator lead that was damaged due to an external abrasion, but notes the lead did not have the critical flaw of an earlier version of the device that St. Jude no longer sells.
    | Comment!
  • Jun. 22, 2012, 4:11 PM
    St. Jude Medical (STJ +2.6%) jumps at the close after a last-minute release of comments on a database report suggesting a single Durata defibrillation lead was damaged by external abrasion - different from the inside-out abrasion seen previously on Riata leads. (previously)
    | Comment!
  • Jun. 18, 2012, 1:10 PM
    Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis.
    | 3 Comments
  • Jun. 14, 2012, 7:32 PM
    A class action lawsuit charges St. Jude Medical (STJ) with misrepresenting facts around the company's Riata and Riata ST defibrillator leads (discontinued last year). Plaintiffs say protruding wires on those and other products caused short circuits that the company failed to disclose.
    | Comment!
  • Jun. 12, 2012, 12:44 PM
    St. Jude Medical (STJ -5.5%) shares plunge suddenly on a report that the company's Durata defribilator is linked to a cable defect. STJ has had a similar problem with its Riata lead, which is no longer on the market; the company has said Durata leads, which it still sells, don't have the problem because they use a different type of insulation material.
    | Comment!
  • May 31, 2012, 5:05 PM
    Dividend yields look increasingly attractive vs. record low Treasury yields, and Morgan Stanley argues the payout ratio of dividend stocks is near an all-time low and could increase substantially. The firm adds T to its dividend portfolio while removing XOM and UNP; "fundamentally and quantitatively attractive" are CVX, MET, FCX, BEN, CAH, FITB, STJ, SPLS.
    | 4 Comments
  • May 14, 2012, 1:26 PM
    St. Jude Medical (STJ +2.1%) ticks higher after being upgraded to Buy at Goldman. The firm cites share gains in its core markets and entrance into new therapeutic categories, which could accelerate revenue growth through 2015. It also raises its price target to $50 from $45.
    | Comment!
  • May 9, 2012, 3:08 PM
    St. Jude Medical (STJ +3.5%) trades up after the FDA approves its Ellipse implantable cardioverter defibrillator. Designed with feedback from more than 200 physicians, the Ellipse offers physicians unique advancements, and is designed to increase patient comfort and physician ease-of-use. Separately, Morgan Stanley upgraded the shares to Overweight this morning, saying it expects the company to benefit from new cardio markets and reduced Durata concerns.
    | Comment!
  • May 2, 2012, 10:40 AM
    Edwards Lifesciences (EW +0.9%) shrugs off this mornings weakness after the Centers for Medicare & Medical Services announced it will cover Transcatheter Aortic Valve Replacement procedures for the treatment of symptomatic aortic valve stenosis, for which EW's Sapien is a marquee product. Separately, Wells Fargo ups the shares to Outperform on the news.
    | Comment!
  • May 1, 2012, 11:49 AM
    New J&J (JNJ) CEO Alex Gorsky is looking to strengthen the company's medical-device unit via takeovers, he tells Bloomberg in an interview. "We remain committed to cardiovascular," Gorsky says, despite sales shrinking 44% since 2006. On the analyst wish list are Edwards Lifesciences (EW) and St. Jude Medical (STJ).
    | 2 Comments
Visit Seeking Alpha's
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.